linjc16/ctgov huggingface dataset:
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A

Study Overview
=================
Brief Summary
-----------------
In patients expressing the SCN5A-E1784K mutation (Glu1784Lys), cardiovascular risk is difficult to define as the stratification of these patients is challenging. From our experience, major cardiovascular events (MCE) tend to occur more frequently in patients expressing overlap syndrome phenotype (Brugada syndrome and Long QT syndrome type 3)than in patients expressing a single phenotype (whether Brugada syndrome or Long QT syndrome type 3). This trials is led on the impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A ( RISKOVER )

Detailed Description
-----------------
Study design: This study will compare the occurrence of MCE between patients with overlap syndrome phenotype and patients with a single phenotype (whether Brugada syndrome or Long QT syndrome type 3) in a cohort of patients 12 years of age and older with the SCN5A-E1784K mutation. Eligible patients will be identified nationwide and included retrospectively and prospectively. Occurrence of MCE between the group  overlap syndrome  and the group  single phenotype  will be compared.

Official Title
-----------------
Impact on Risk Stratification of Overlap Syndrome Phenotype (Brugada and Long QT Type 3) in Patients With E1784K Mutation in SCN5A

Conditions
-----------------
Long QT Syndrome, Brugada Syndrome, Cardiac Conduction System Disease, Arrhythmias, Cardiac

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: genotype E1784K (glu1784lys) in SCN5A gene Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| E1784K (glu1784lys) in SCN5A expressing either Long QT syndrome type 3 or Brugada syndrome<br> | |
| E1784K (glu1784lys) in SCN5A expressing both syndromes (Long QT syndrome and Brugada syndrome)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of MCE | occurrence of syncop, sudden cardiac death, ventricular arrhythmia, cardiopulmonary arrest collected by a series of medical questions | at inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Long QT syndrome type 3, Brugada Syndrome, SCN5A gene, E1784K mutation, Cardiac arrhythmias, Cardiac conduction system disease, phenotypic overlap, overlap syndrome, sodium channelopathie
Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life

Study Overview
=================
Brief Summary
-----------------
The aims of the research are: To predict factors affecting hand dysfunction in patient with rheumatoid arthritis To study the effect of hand dysfunction on quality of life in patient with rheumatoid arthritis

Detailed Description
-----------------
Rheumatoid Arthritis (RA) is the most common chronic autoimmune systemic inflammatory arthritis, associated with considerable impairments of Quality of life . Hand is the principle means by which an individual interacts with people and objects in the external environment .Many factors affect hand function in addition to arthritis ,. Many RA patients suffer from an increased loss of muscle mass with a significant impact on these patients' quality of life , and also Distal sensory, mixed sensorimotor, mononeuritis multiplex and entrapment neuropathy are the most commonly reported types of neuropathy in RA .So assessment of factors causing hand dysfunction can provide us a quick and early insight on the debilitating effects of RA on functioning and disability.Thus Early intervention can then be initiated which will help limit joint damage and thereby improve functional outcomes.

Official Title
-----------------
Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Patients who fulfilled the American College of Rheumatology (ACR) (2010) criteria for RA, attending the Rheumatology and Rehabilitation outpatient clinic and in-patient department, Faculty of Medicine, Assuit University Hospitals. Exclusion Criteria: Patients with other rheumatic diseases. Patients less than 18 years old. Patients with co-morbidities influencing disease activity and hand function (e.g., end- stage liver or renal disease, serious infections, or severe cardiac, respiratory, gastrointestinal disease) . Patient with any recent history of hand trauma, or surgery. Patient with neurological involvement as , peripheral neuropathy and radiculopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life | Health assessment questionnaire disability index (HAQ) | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hand function | measured by musculoskeletal ultrasound | one year |
Cytokine Regulation of Periradicular Pain in Humans

Study Overview
=================
Brief Summary
-----------------
This clinical trial evaluates the role of cytokines in patients needing root canal treatment with diagnosis of necrotic pulp and chronic apical periodontitis

Detailed Description
-----------------
This study evaluates whether periradicular exudate concentrations of cytokines differ in patients experiencing pain and mechanical allodynia due to pulpal necrosis with an acute exacerbation of a chronic apical periodontitis, as compared to patients with pulpal necrosis with chronic apical periodontitis, but no pain or mechanical allodynia

Official Title
-----------------
Cytokine Regulation of Periradicular Pain in Humans

Conditions
-----------------
Chronic Apical Periodontitis of Pulpal Origin

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be at least 16 years of age. Clinical indication for Non-Surgical Root Canal Therapy (NSRCT). 1st or 2nd maxillary or mandibular molar Diagnosis must be Chronic Apical Periodontitis (CAP) with or without symptoms. Intact, mature apices. ASA I or II Exclusion Criteria: Failure to meet any of the above Previous NSRCT Previous pulpotomy or pulpectomy Suppurative apical periodontitis Patients taking medications which can affect their pain rating or medications which effect their immune system ( such as glucocorticoids)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain
Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents

Study Overview
=================
Brief Summary
-----------------
The bleeding rate of both EGD (including biopsy) and colonoscopy (including biopsy or cold snare polypectomy) in patients who continue to take various antithrombotic drugs is studied prospectively. The immediate or delayed bleeding that requires hemostatic clipping or other endoscopic treatments is defined as the bleeding. Immediate bleeding requiring hemostatic clipping is defined as spurting or oozing which continued for more than 30 seconds. Delayed bleeding is defined as bleeding that requires the endoscopic treatment within 2 weeks after endoscopy. Prophylactic clipping is not performed after taking biopsy and doing polypectomy. Additionally, investigators evaluate the rate of injured submucosal arteries of the excised specimen when the bleeding occurs.

Conditions
-----------------
Bleeding After GI Endoscopy

Intervention / Treatment
-----------------
* Procedure: Biopsy or cold snare polypectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion criteria is all patients who continue to take antithrombotic drugs and undergo EGD or colonoscopy Exclusion Criteria: Patients who take prophylactic clipping after biopsy or polypectomy American Society of Anesthesiologists physical status of class IV or V

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Biopsy or cold snare polypectomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the rate of delayed bleeding | Delayed bleeding defined as bleeding that required endoscopic treatment within 2 weeks after the procedure. | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the rate of immediate bleeding | Immediate bleeding defined as spurting or oozing which continued for more than 30 seconds. | 10 years | 
| the number of clip used | The number of clip used during the procedures. | 10 years |
Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations

Study Overview
=================
Brief Summary
-----------------
Heart failure (HF) is a serious chronic disease with frequent readmissions, some of which can be prevented by early action. The management of HF is complex: long, often difficult and costly. In France, nearly one million people suffer from HF and 120,000 new cases are diagnosed every year. With the aging population, this number will continue to evolve and become a real public health problem. Within 10 to 20 years ahead, WHO projects that heart failure in either the 3 most common diseases in industrialized countries. The objective of the project is to test an intelligent platform for monitoring at home, using non-intrusive sensors, patients with heart failure, particularly those with stage II and III NYHA. It will assist the medical automating the processing of information from these sensors to detect and report an early stage risk situations. Patient monitoring, by a system of telemedicine tools associated with motivation and education helps significantly reduce the number of days of hospitalization becomes important when the patient is hospitalized for acute HF.

Official Title
-----------------
Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations Derived From Non Intrusive Sensors and Devices

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Other: Equiped group with telemedicine systems


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Population with heart failure stage II and III Exclusion Criteria: Population whose age is less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Groupe 1: experimental group<br>Equiped group with telemedicine systems | Other: Equiped group with telemedicine systems<br> <br> |
| Groupe 2: control group<br>Non equiped group with telemedicine systems | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anticipation and detection of heart failure with automatic treatment of information derived from non intrusive sensors and devices |  | patient's medical data will be controlled remotely by health professional for the duration of hospital stay, up to 1 year] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, telemonitoring, intrusive sensors, intrusive devices, Heart failure stage II, Heart failure stage III, heart disease
Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

Study Overview
=================
Brief Summary
-----------------
Osteoporotic fractures of the hip are a major cause of admission to long-term care facilities. Such fractures put patients at high risk for further fractures, pain and disability. Current data show that many patients in long-term care facilities do not receive FDA medications for their osteoporosis. This trial will test whether a multi-model intervention (which provides feedback about provider use of osteoporosis medications, information about osteoporosis, and currently approved osteoporosis medications)directed at physicians, other health care providers, and nurses will improve the number of prescriptions written for FDA approved medications for osteoporosis treatment.

Official Title
-----------------
Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities Written for FDA Approved Medications for Osteoporosis Treatment.

Conditions
-----------------
Hip Fractures, Osteoporosis

Intervention / Treatment
-----------------
* Behavioral: Long-term care facilities in the intervention arm will receive education and feedback audit on performance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any North Carolina long-term care facility with ten residents who had had a hip fracture or osteoporosis diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Long-term care facilities in the intervention arm will receive education and feedback audit on performance|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of new prescriptions for FDA-Approved osteoporosis medications. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary Outcome Measures: Changes in number of bone mineral density test ordered, change in the number of hip protectors issued, change in the number of prescriptions for calcium and vitamin D, changes in the rate of new osteoporotic fractures. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
All NC LTC facilities having ten residents with a hip fracture or osteoporosis on the MDS will be invited to participate in the trial
Cytokine Hemoadsorption in ECMO Patients

Study Overview
=================
Brief Summary
-----------------
Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.

Official Title
-----------------
Cytokine Hemoadsorption in ECMO Patients

Conditions
-----------------
SIRS, Cytokine Storm, Cardiogenic Shock, Cardiac Arrest, Septic Shock, ARDS, Human

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: VA/VV ECMO hemoadsorption Age ≥ 18 years Exclusion Criteria: no additional exclusion criteria after being eligible for ECMO

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Veno-arterial ECMO patients<br>Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption. | |
| Veno-venous ECMO patients<br>Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Haemodynamic stabilization | Decreased need for vasopressors according to vasoactive-inotropic score and increase in mean arterial pressure | Within 12 hours after hemoadsorption | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lactate, interleukin-6, C-reactive protein and procalcitonin clearance |  | Within 12 hours after hemoadsorption | 
| Weaning from ECMO |  | from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days | 
| ICU length of stay |  | from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days | 
| Hospital mortality |  | from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemoadsorption, ECMO, SIRS, ARDS, Post-resuscitation syndrome, ECPR
Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
The discovery of the role of endothelial progenitor cells (EPCs) and their involvement in the cardiovascular complications of type 2 diabetes (T2DM) would quickly have a significant impact on the millions of Americans who have T2DM. This project is designed to 1) determine the mechanisms underlying EPC dysfunction in older, sedentary adults with T2DM compared those with normal glucose metabolism and impaired glucose metabolism, and 2) determine if aerobic exercise training is an efficacious therapy for EPC dysfunction in T2DM, and whether improvement in EPC number and function translates to improved endothelial function, increased capillarization, and improved glucose metabolism in T2DM.

Official Title
-----------------
Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Aerobic Exercise Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 50-80 Non-smoker If woman, postmenopausal >1 year Exclusion Criteria: History of heart disease or stroke Cancer Poorly controlled hypertension or dyslipidemia Kidney or Liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: T2DM<br>Type 2 Diabetes Mellitus | Other: Aerobic Exercise Training<br>* 6 months of aerobic exercise training, 3 days per week<br>|
| Experimental: IGT<br>Impaired Glucose Tolerance | Other: Aerobic Exercise Training<br>* 6 months of aerobic exercise training, 3 days per week<br>|
| Active Comparator: NGT<br>Normal Glucose Tolerance | Other: Aerobic Exercise Training<br>* 6 months of aerobic exercise training, 3 days per week<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial progenitor cell number |  | Baseline | 
| Endothelial progenitor cell number |  | 6-month | 
| Skeletal muscle capillarization |  | Baseline | 
| Skeletal muscle capillarization |  | 6-month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiorespiratory Fitness |  | Baseline | 
| Cardiorespiratory Fitness |  | 6-month |